- Design, synthesis, biological and structural evaluation of functionalized resveratrol analogues as inhibitors of quinone reductase 2
-
Resveratrol (3,5,4′-trihydroxylstilbene) has been proposed to elicit a variety of positive health effects including protection against cancer and cardiovascular disease. The highest affinity target of resveratrol identified so far is the oxidoreductase enzyme quinone reductase 2 (QR2), which is believed to function in metabolic reduction and detoxification processes; however, evidence exists linking QR2 to the metabolic activation of quinones, which can lead to cell toxicity. Therefore, inhibition of QR2 by resveratrol may protect cells against reactive intermediates and eventually cancer. With the aim of identifying novel inhibitors of QR2, we designed, synthesized, and tested two generations of resveratrol analogue libraries for inhibition of QR2. In addition, X-ray crystal structures of six of the resveratrol analogues in the active site of QR2 were determined. Several novel inhibitors of QR2 were successfully identified as well as a compound that inhibits QR2 with a novel binding orientation.
- St. John, Sarah E.,Jensen, Katherine C.,Kang, Soosung,Chen, Yafang,Calamini, Barbara,Mesecar, Andrew D.,Lipton, Mark A.
-
p. 6022 - 6037
(2013/09/23)
-
- PYRIMIDINE AND QUINAZOLINE DERIVATIVES
-
This invention is concerned with compounds of the formula ( l ) wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
- -
-
Page/Page column 77-78
(2008/06/13)
-
- PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES
-
This invention is concerned with compounds of the formula wherein A, R1 to R5 are as defined in the specification and G is a pyridine, quinoline or pyrimidine group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
- -
-
Page/Page column 29-30; 34
(2008/06/13)
-
- 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES
-
This invention relates to 4,4-disubstituted piperidine derivatives of the formula wherein A and R1 to R5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceuti
- -
-
Page/Page column 15
(2009/01/20)
-
- ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES
-
This invention relates to compounds of the formula wherein X is O or NR8, Y is CR7 or N, and R1 to R8 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
- -
-
Page/Page column 15
(2009/01/20)
-
- PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES
-
This invention is concerned with compounds of the formulaand pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
- -
-
Page/Page column 38
(2008/06/13)
-
- 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES
-
This invention relates to 4,4-disubstituted piperidine derivatives of the formula (I) wherein A and R1 to R5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmac
- -
-
Page/Page column 30-31
(2009/01/20)
-
- BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES
-
This invention relates to compounds of the formula wherein A, R1 to R3 are as defined in the specification and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridine and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
- -
-
Page/Page column 24
(2008/12/08)
-
- BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES
-
This invention is concerned with compounds of the formula (I) wherein X, A, B, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical
- -
-
Page/Page column 107; 125-126; 130-132; 134-135; 140; 142-143; 146;
(2008/06/13)
-
- Stereo- and regioselective glycosylates to the Bis-C-arylglycoside of kidamycin
-
In explorations toward the total synthesis of the antitumor anthrapyran natural product kidamycin, the regioselective introduction of aminosugars angolosamine and vancosamine as C-arylglycosides has been accomplished onto hydroxylated anthrapyran aglycone
- Fei, Zhongbo,McDonald, Frank E.
-
p. 3547 - 3550
(2008/02/12)
-
- Pyrimidine, quinazoline, pteridine and triazine derivatives
-
This invention is concerned with compounds of the formula wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
- -
-
Page/Page column 44; 49
(2008/06/13)
-
- Design of potent PPARα agonists
-
Computational analysis of the ligand binding pocket of the three PPAR receptor subtypes was utilized in the design of potent PPARα agonists. Optimum PPARα potency and selectivity were obtained with substituents having van der Waals volume around 260. Compound 6 had a PPARα potency of 0.002 μM and a selectivity ratio to PPARγ and PPARδ of 410 and 2000, respectively.
- Sauerberg, Per,Mogensen, John P.,Jeppesen, Lone,Bury, Paul S.,Fleckner, Jan,Olsen, Grith S.,Jeppesen, Claus B.,Wulff, Erik M.,Pihera, Pavel,Havranek, Miroslav,Polivka, Zdenek,Pettersson, Ingrid
-
p. 3198 - 3202
(2008/02/05)
-
- Laccase-catalyzed dimerization of hydroxystilbenes
-
A series of hydroxystilbenes, analogues of the bioactive phytoalexin resveratrol, were synthesized and submitted to the catalytic action of a laccase from Trametes pubescens in a biphasic system made of ethyl acetate and acetate buffer. Oxidation took place at the 4′-hydroxy (4-hydroxy) position of the hydroxystilbenic moieties, followed by radical-radical coupling dimerization reactions. Most of the products were isolated in good yields and fully characterized. Depending on the substrates, three different dimeric products could be identified, the main products usually being 4-O-α-β-5 (dihydrofuran-like) dimers.
- Ponzoni, Chiara,Beneventi, Elisa,Cramarossa, Maria Rita,Raimondi, Stefano,Trevisi, Giulia,Pagnoni, Ugo Maria,Riva, Sergio,Forti, Luca
-
p. 1497 - 1506
(2008/09/17)
-
- Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
-
This invention is concerned with compounds of the formula wherein A, B1, B2, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
- -
-
Page/Page column 80
(2010/11/23)
-
- A re-investigation of resveratrol synthesis by Perkins reaction. Application to the synthesis of aryl cinnamic acids
-
A re-investigation of resveratrol synthesis by Perkins reaction allowed to improve this method and to determine the configuration of the intermediates. The results were applied to the synthesis of several aryl cinnamic acids for biological evaluation.
- Solladié, Guy,Pasturel-Jacopé, Yacine,Maignan, Jean
-
p. 3315 - 3321
(2007/10/03)
-
- Compounds, their preparation and use
-
The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
- -
-
-
- META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS
-
The present invention relates to a class of compounds represented by the Formula Ior a pharmaceutically acceptable salt thereof, whereinA ispharmaceutical compositions thereof and methods of using such compounds and compositions as alphavbeta3 antagonists.
- -
-
-
- Huazhongilexone is not 3′,5,5′,7-tetrahydroxyflavanone. Preparation of 3′,5′-dimethoxy-5,7-dihydroxyflavanone
-
Huazhongilexone, isolated from Ilex centrochinensis, was originally assigned the structure 3′,5,5′,7-tetrahydroxyflavanone. The racemic flavanone has been synthezised. Huazhongilexone is different from the synthetic compound and thus must have a different structure. In addition the new (±)-3′,5′-dimethoxy-5,7- dihydroxyflavanone has been prepared and characterized. Acta Chemica Scandinavica 1998.
- Anthoni, Uffe,Encarnacion D., Rosalba,Nielsen, Per H.,Christophersen, Garsten
-
p. 1243 - 1246
(2007/10/03)
-
- Phenanthrene Synthesis: Coeloginin a Novel 9,10-Dihydrophenanthrene from the Orchid Coelogyne cristata
-
The synthesis of 2,6-dihydroxy-7,8-dimethoxy-9,10-dihydro-5H-phenanthropyran-5-one (coeloginin) (1), a natural product isolated from the orchid Coelogyne cristata, is described.The key step involved the treatment of methyl 9,10-dihydro-5,7-di-iso
- Sargent, Melvyn V.,Stanojevic, Edi
-
p. 1919 - 1921
(2007/10/02)
-